open ended clinical trial of ciprofloxacin in upper respiratory tract infections

Ciprofloxacin is a 4-quinolone derivative with a broad antibacterial spectrum covering gram-negative rods particularly pseudomonas and gram-positive cocci. A clinical trail was conducted in randomly selected 69 patients with upper respiratory tract infections. The drugs was given in oral form in equal dosage on 6 hourly basis [250 and 500 mg]. The response rate was 96.6% with symptoms and signs disappearing by 3rd day in 35 [60.34%] patients, by 5th day in 21 patients [32.6%]. Bacterological profile showed excellent response in all the patients